Dr Takahiro Yamamoto

Dr Yamamoto is an MHRA-accredited First-in-Human (FIH) Principal Investigator at Hammersmith Medicines Research (HMR), specialising in the conduct of early-phase clinical trials.

Since joining HMR in 2020, he has served as Principal Investigator on more than 20 Phase I studies, including multiple first-in-human trials. He brings extensive experience in study oversight, protocol development and execution, and safety management, with a strong emphasis on participant safety, data integrity, and operational efficiency. He ensures that all studies are conducted in strict accordance with Good Clinical Practice, regulatory requirements, and sponsor expectations.

Dr Yamamoto is listed on the GMC Specialist Register in Clinical Pharmacology and Therapeutics and General Internal Medicine. He completed his postgraduate medical training at leading NHS institutions in London and Cambridge, where he gained broad experience across both acute and specialist medical services. He has authored and co-authored multiple peer-reviewed publications in clinical pharmacology and toxicology, reflecting sustained engagement in research that underpins his approach to early-phase drug development.